NEW YORK (GenomeWeb News) – Danaher today reported sales in its Life Sciences & Diagnostics segment more than doubled in the second quarter from a year ago, while total revenues grew 25 percent.

For the three months ended June 29, the Life Sciences & Diagnostics business posted revenues of $1.58 billion, up 125 percent from $704.8 million a year ago as acquisitions added 123 percentage points to the growth while the segment's core business grew 5 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.